These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Antipsychotic drugs: the costs and benefits. Harv Ment Health Lett; 2007 Mar; 23(9):5-6. PubMed ID: 17390404 [No Abstract] [Full Text] [Related]
3. Cost-effectiveness measures, methods, and policy implications from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for schizophrenia. Rosenheck RA; Lieberman JA J Clin Psychiatry; 2007 Feb; 68(2):e05. PubMed ID: 17335313 [TBL] [Abstract][Full Text] [Related]
4. [Expensive but nevertheless cost effect? Pharmacoeconomics of atypical neuroleptics]. Laux G; Günther W Pharm Unserer Zeit; 2002; 31(6):572-6. PubMed ID: 12481515 [No Abstract] [Full Text] [Related]
5. Second-generation antipsychotics: cost-effectiveness, policy options, and political decision making. Rosenheck RA; Leslie DL; Doshi JA Psychiatr Serv; 2008 May; 59(5):515-20. PubMed ID: 18451007 [TBL] [Abstract][Full Text] [Related]
6. Outcomes, costs, and policy caution. A commentary on: the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Rosenheck RA Arch Gen Psychiatry; 2006 Oct; 63(10):1074-6. PubMed ID: 17015809 [No Abstract] [Full Text] [Related]
7. Developing a policy for second-generation antipsychotic drugs. Rosenheck RA; Sernyak MJ Health Aff (Millwood); 2009; 28(5):w782-93. PubMed ID: 19622538 [TBL] [Abstract][Full Text] [Related]
8. Antipsychotic drugs and schizophrenia. Gupta N; Basu D N Engl J Med; 2006 Jan; 354(3):298-300; author reply 298-300. PubMed ID: 16422018 [No Abstract] [Full Text] [Related]
9. Drug treatments for schizophrenia. Adams C; Wilson P; Gilbody S; Bagnall AM; Lewis R Qual Health Care; 2000 Mar; 9(1):73-9. PubMed ID: 10848375 [No Abstract] [Full Text] [Related]
10. Cost-effectiveness of schizophrenia pharmacotherapy. Soumerai SB; Law MR Am J Psychiatry; 2007 Apr; 164(4):678; author reply 678-9. PubMed ID: 17403984 [No Abstract] [Full Text] [Related]
11. Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia. Revicki DA J Psychiatry Neurosci; 1997 Jul; 22(4):256-66. PubMed ID: 9262048 [TBL] [Abstract][Full Text] [Related]
12. Lessons to take home from CATIE. Carpenter WT; Buchanan RW Psychiatr Serv; 2008 May; 59(5):523-5. PubMed ID: 18451009 [TBL] [Abstract][Full Text] [Related]
14. Czech government's move to cut drug costs sparks protests. Krosnar K BMJ; 2005 Jan; 330(7482):62. PubMed ID: 15637365 [No Abstract] [Full Text] [Related]
15. Cost-benefits of new drugs. Daniel DG; Moseley C; Rosenfield S; Wolf S; Nawroz S Psychiatr Serv; 1995 Aug; 46(8):835-6. PubMed ID: 7583490 [No Abstract] [Full Text] [Related]
16. Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE). Lieberman JA Arch Gen Psychiatry; 2006 Oct; 63(10):1069-72. PubMed ID: 17015808 [No Abstract] [Full Text] [Related]
17. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care. Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216 [TBL] [Abstract][Full Text] [Related]